Hepatology 2002; 35: 182–189. 54  Williams I, Churchill D, MAPK inhibitor Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13(Suppl 2):1–85. 55  Ghany MG, Strader DB, Thomas DL, Seeff LB for the American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374. 56  Soriano V, Puoti M, Sulkowski M et al.

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073–1089. 57  Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J

Gastroenterol 2005; 100: 2338–2354. 58  Avidan NU, Goldstein D, Rozenberg L et al. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr 2009; 52: 452–458. 59  Pascual-Pareja JF, Caminoa A, Larrauri C et al. HAART is associated with lower necro-inflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 count of more than 350 cells/microl at the time of liver biopsy. AIDS 2009; 23: 971–975. 60  Marra F, Bruno R, Galastri S. gp120 induces directional migration of human hepatic stellate cells: a link between HIV check details infection and liver fibrogenesis. Hepatology 2007; 46: Abstract A125. 61  Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26: 2–18. 62  Aoyama T, Paik Megestrol Acetate YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract 2010; Article ID 192543, 8 pages. 63  Jacobson IM, McHutchison

JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416. 64  Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196: 670–676. 65  Amorosa VK, Slim J, Mounzer K et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010; 15: 91–99. 66  Kakuda T, Leopold L, Nijs S et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial. 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain. March 2012 [Abstract O_18]. 67  Hammond K, Wolfe P, Burton J et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV-seronegative volunteers.